Colorado researcher gets $1 million to advance Alzheimer's drug trial
The Denver Post
Researcher Huntington Potter, director of the Rocky Mountain Alzheimer’s Disease Center and a University of Colorado professor, has been awarded $1 million to advance his clinical trial that focuses on treating neuroinflammation to slow or halt the disease.
The funding is part of a $7 million investment by the Alzheimer’s Association and California philanthropist Michaela “Mikey” Hoag that boosts four promising approaches to addressing neuroinflammation — with another $3 million waiting for the trial that proves most promising.
Potter’s research involves testing the drug Leukine, already approved for treating infections from chemotherapy, to treat neuroinflammation in the brain. Potter also directs Alzheimer’s research at the Linda Crnic Institute for Down Syndrome at CU’s Anschutz Medical Campus. People with Down syndrome have an increased risk of dementia at an earlier age.
The competitive funding reflects growing evidence of neuroinflammation’s role in Alzheimer’s disease and seeks to understand how the natural immune response of inflammation, which the body uses to fight infection or repair tissue, can be stopped from damaging nerve cells in the brain.
Other winners of $1 million in funding represent the Institute of Health Carlos III in Barcelona, Spain; a collaboration between the Longeveron life sciences company and the University of Miami; and the University of California, Davis.
To apply to participate in the research, individuals can register with the Alzheimer’s Association’s TrialMatch program or call 800-272-3900.